News >

Goy Reflects on MCL Data Presented at ASH 2017

Angelica Welch
Published: Wednesday, Dec 13, 2017

Andre Goy, MD

Andre Goy, MD
With the excitement of the recent FDA approval of acalabrutinib (Calquence) still moving through the field of mantle cell lymphoma (MCL), there was much anticipation for additional abstracts in the field at the 2017 ASH Annual Meeting.

during the meeting, Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, Hackensack Medical Center, shed light on some of these studies as well as future treatment options for patients with MCL.

OncLive: Can you discuss some of the data in MCL that were presented at this year’s meeting?

Goy: At the 2017 ASH Annual Meeting, we have shown the continued progress on the impact of novel therapies, cellular therapies, and immunotherapies. In MCL, we are seeing a continuous shift of novel agents that are changing the landscape as we combine them in the relapse setting, and potentially in the frontline setting. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x